GEN-MKT-18-7897-A
Jan 29, 2023 | Biopharma, Blogs, Echo® MS+ system, Pharma | 1 comment
You asked, we answered! With analysis speeds of at least 1 sample per second, the Echo® MS system has created a buzz in the industry. This is up to 50x faster than conventional LC-MS/MS. This revolutionary tool for drug discovery and development has led to many questions from scientists and researchers around the world. We answer the top 7 Echo® MS system questions here.
The sample ejection volume for the Echo® MS system is about 0.1% of what you are injecting into an LC-MS system. Therefore, you are putting many fewer contaminants into the system over the same period of time.
The SCIEX OS software controls the system. This allows us to automatically process the data and export the results to any visualization software or LIMS. The SCIEX OS API (Application Programming Interface) allows integration with automation software from robotics vendors.
What types of liquid handling systems can be interfaced upstream of the Echo MS system? And what plate/sample throughput rates are possible?
The system is compatible with any vendor’s robotics system that can manage 384- and 1536-well plates. The cycle time for 384-well plates is less than 10 minutes, and for 1536-well plates it is less than 30 minutes.
The total size of the system is approximately 1.3 meters x 1.4 meters. This does not include the acquisition computer (which can be located up to 2 meters from the system) or the 1 meter of service access required around the entire system.
For a 384-well plate, the minimum volume required in the well is 20 µL and for 1536-well plates the minimum volume required is 3 µL. This is to ensure efficient ejection of the sample droplet.
Do you have a question? Please submit your question today or add it below in the comments.
Learn more about what the Echo® MS system can do for your lab at sciex.com/echoms. You will be able to see inside the system, download the brochure, gain access to technical notes, watch the video and request a quote.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
nice
You must be logged in to post a comment.
Share this post with your network